Haleon plc Files Form 6-K: Director Declaration

Ticker: HLNCF · Form: 6-K · Filed: Oct 3, 2024 · CIK: 1900304

Sentiment: neutral

Topics: routine-filing, director-declaration, foreign-issuer

TL;DR

Haleon plc filed a 6-K for a Director Declaration on Oct 3, 2024. No major financial news.

AI Summary

Haleon plc filed a Form 6-K on October 3, 2024, reporting a "Director Declaration." This filing is a routine report for foreign private issuers and does not contain specific financial figures or operational updates beyond the declaration itself.

Why It Matters

This filing indicates a routine corporate action by Haleon plc, a significant player in the consumer healthcare market, which is standard for foreign private issuers reporting to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard procedural document (Director Declaration) and does not contain market-moving financial information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing for Haleon plc?

A Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report information that the company has made or is required to make public in its home country.

What specific information is contained in Exhibit 99.1 of this filing?

Exhibit 99.1 is described as a 'Director Declaration' dated 03 October 2024.

Does this filing include financial results for Haleon plc?

No, this Form 6-K specifically reports a 'Director Declaration' and does not appear to contain financial results or operational updates.

When was Haleon plc incorporated or when did its name change?

The filing indicates a former company name 'DRVW 2022 Ltd' with a date of name change on 20211217.

What is Haleon plc's primary business sector?

Haleon plc is classified under Standard Industrial Classification code 2844 for 'Perfumes, Cosmetics & Other Toilet Preparations'.

Filing Stats: 325 words · 1 min read · ~1 pages · Grade level 12.6 · Accepted 2024-10-03 09:49:10

Filing Documents

From the Filing

DECLARATION a8367g UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of October 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description  99.1   03 October 2024 - “Director Declaration”     99.1       Haleon plc: Director Declaration     3 October 2024:   In accordance with paragraph 6.4.9R of the Listing Rules,   Haleon plc hereby gives notification that Alan Stewart   stepped down from the Board of Diageo plc on 26 September 2024.     Amanda Mellor   Company Secretary     About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit  www.haleon.com .                SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: October 03, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing